soul trial oral semaglutide cardiovascular outcomes results 2025 nejm ๐ Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no NEJM Editorial Fellow Harleen Marwah,
Pay in 4 interest-free payments of $5.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Oct 8 - Oct 13

























